Why pain medicine and physical medicine practices separate vendor review
Pain management and physical medicine practices often carry two parallel product categories, Wharton's jelly allografts and exosome products, and treat them as separate line items in vendor review because they sit under different regulatory frameworks. A practice's compliance process typically confirms vendor registration status, requests a sample certificate of analysis, and records that review in the practice's own file rather than relying on a supplier's marketing materials.
Knoxville
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
84- Pain Medicine
- 43
- Physical Medicine & Rehabilitation
- 41
Medical director and state board verification
Because Precision Biologics does not provide clinical guidance, practices verify with their own medical director and, separately, with the Tennessee Board of Medical Examiners or the relevant state licensing board, whether a given intended use fits their regulatory posture. That determination, along with any procedure-level decision, belongs to the practice and its counsel.
Receiving shipments in the Southeast
Cryopreserved Wharton's jelly formats arrive overnight on dry ice in validated containers and require storage at -80 degrees Celsius on arrival; lyophilized exosome and Wharton's jelly formats are shelf-stable and do not need cryogenic storage. A practice's intake process should log the lot identifier and any temperature indicator against the shipment's certificate of analysis before the product enters inventory.
Account setup with Precision Biologics
New accounts are verified against the NPPES registry using the practice's NPI number, after which documentation such as donor eligibility summaries and lot release records becomes available on request. Peer-to-peer calls are available to walk through documentation questions; pricing is disclosed only to verified accounts.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a physical medicine practice in Knoxville open an account separately from an affiliated pain medicine group?+
Yes. Accounts are verified at the individual or group NPI level, so affiliated practices can hold separate accounts if each has its own NPI and billing arrangement.
Do you provide guidance on which product fits a specific pain management protocol?+
No. Precision Biologics supplies documentation about product composition and processing; decisions about intended use and procedure protocol are made by the practice and its own clinical and legal counsel.
What's the difference in how Wharton's jelly and exosome products are regulated?+
Wharton's jelly products are offered under the supplier's HCT/P framework, while exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act. Whether a specific use qualifies under either framework is a determination for your practice and counsel, not something Precision Biologics advises on.